Evaluation of the Cyberknife Precision Radiation Delivery System for Unresectable Malignant Lung Tumors - A Phase I/II Study
1.Lung tumor >= 5.0 cm.
2.Age > 18 years,
3.Histologic confirmation of malignancy (primary lung or metastatic tumor)
4.Deemed unresectable either by radiographic criteria (such as direct invasion of the
mediastinum, heart, great vessels, or trachea), by virtue of excessive risk to patient,
patient refusal to undergo surgery, or prior operative findings.
5.Performance status of 0-2 by Eastern Clinical Oncology Group criteria
Exclusion Criteria:1. No chemotherapy within 2 weeks of radiation treatment.
2. Refusal to sign informed consent.
3. Refusal to take a pregnancy test prior to treatment if the patient is a woman with
child bearing potential.
Type of Study:
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximal tolerated dose (MTD) that can be delivered with stereotactic radiosurgery in patients with inoperable malignant lung tumors
Outcome Time Frame:
Dr. Billy W. Loo Jr. M.D. Ph.D.
United States: Institutional Review Board
- Lung Cancer
- Lung Neoplasms
|Stanford University School of Medicine
||Stanford, California 94305-5317